Combined worldwide sales of Neulasta ® ( pegfilgrastim ) and NEUPOGEN ® ( Filgrastim ) increased 4 percent to $ 1,254 million in the third quarter of 2010 versus $ 1,210 million for the third quarter of 2009 . Combined sales of Neulasta and NEUPOGEN in the U.S. were $ 942 million in the third quarter of 2010 versus $ 897 million in the third quarter of 2009 , an increase of 5 percent due primarily to an increase in the average net sales price . Combined international sales were $ 312 million in the third quarter of 2010 versus $ 313 million for the third quarter of 2009 . Excluding the $ 6 million unfavorable impact of foreign exchange , international product sales increased 2 percent , reflecting continued conversion from NEUPOGEN to Neulasta .